Such combination therapeutic strategy would likely improve patient survival by targeting the specific form of LSD1 modulating the tumour microenvironment to impede not only tumour burden but recurrence resulting in a favorable anti-tumour environment. This evidence concerns the gene KDM1A and neoplasm.